Pristiq
Generic name: desvenlafaxine
Treatment for: Depression
Re-formatted Data Submission Results in Extension of FDA Review for Desvenlafaxine Succinate
MADISON, N.J., August 29, 2006 -- Wyeth announced today it has been notified by the U.S. Food and Drug Administration (FDA) that the agency has extended by three months the action date for its review of the New Drug Application (NDA) for desvenlafaxine succinate extended release for the treatment of major depressive disorder. The FDA's revised action date for the NDA for desvenlafaxine succinate will now be January 22, 2007.
The FDA has the option of extending the typical 10-month review period if a sponsor submits a major amendment, as defined by the FDA, during the last three months of the review. In this instance, Wyeth had submitted its analyses of pre-clinical carcinogenicity data in study reports as part of the original NDA in December 2005, and subsequently submitted the raw data sets from these studies.
Wyeth had to resubmit that same raw data in the required format on July 31, 2006, which fell during the last three months of the FDA's review period. The decision to extend the review period was based solely on the submission of re-formatted data sets. The Agency has not communicated any new concerns regarding the NDA submission. This extension is not likely to have any bearing on the current launch plans.
Posted: August 2006
Related articles
- FDA Approves Pristiq for the Treatment of Adult Patients with MajorDepressive Disorder - March 3, 2008
- Wyeth Receives Approvable Letter from FDA for Pristiq for the Treatment of Vasomotor Symptoms Associated with Menopause - July 24, 2007
- Wyeth Receives Approvable Letter From FDA for Pristiq (Desvenlafaxine Succinate) for the Treatment of Major Depressive Disorder - January 23, 2007
- FDA Cancels Advisory Committee Meeting to Review Desvenlafaxine Succinate Data for Major Depressive Disorder - August 22, 2006
- Wyeth Submits Two New Drug Applications for Women's Health Therapies - June 26, 2006
- Wyeth Submits New Drug Application for Desvenlafaxine Extended Release (DVS-233) for Depression - December 22, 2005
Pristiq (desvenlafaxine) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
